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Abstract
As is the case in numerous natural processes, enzymatic phosphorylation can be used in the laboratory to influence the conforma-
tional populations of proteins. In nature, this information is used for signal transduction or energy transfer, but has also been shown
to play an important role in many diseases like tauopathies or diabetes. With the goal of determining the effect of phosphorylation
on amyloid fibril formation, we designed a model peptide which combines structural characteristics of α-helical coiled-coils and
β-sheets in one sequence. This peptide undergoes a conformational transition from soluble structures into insoluble amyloid fibrils
over time and under physiological conditions and contains a recognition motif for PKA (cAMP-dependent protein kinase) that
enables enzymatic phosphorylation. We have analyzed the pathway of amyloid formation and the influence of enzymatic phosphor-
ylation on the different states along the conformational transition from random-coil to β-sheet-rich oligomers to protofilaments and
on to insoluble amyloid fibrils, and we found a remarkable directing effect from β-sheet-rich structures to unfolded structures in the
initial growth phase, in which small oligomers and protofilaments prevail if the peptide is phosphorylated.
Introduction
Amyloid fibrils are one of the most important and studied self-
assembled materials in nature. A wide range of peptides and
proteins with various primary sequences and functions are able
to form these wel organized and highly stable aggregates under
multiple conditions [1]. The morphology ranges from liquid
crystals to ribbons, rigid nanotubes and funnels [2]. Although
amyloid aggregates are mostly known for pathologic events like
Alzheimer’s and Parkinson’s disease or type two diabetes [3-6],
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they also combine the potential for applications with biological
function with desirable mechanical properties. Many such
peptide aggregates display exceptional stability, mechanical
strength, stability at high temperatures and they are resistant
towards enzymatic degradation [2]. Several studies have
demonstrated the utilization of amyloids as functional tem-
plates like conductive nanowires [7], water-filled nanotubes [8]
or biocompatible hydrogels [9]. Likewise, nature uses amyloid-
like cross-β-sheet-rich conformations to store peptide hormones
in secretory granules of the endocrine system [10]. As another
example it was found that mammalian Pmel17 amyloid tem-
plates and accelerates the covalent polymerization of reactive
small molecules into melanin, an important biopolymer that
protects against a broad range of cytotoxic insults, including
UV and oxidative damage [11]. While amyloid morphologies
and events which induce amyloid formation are the subject of
numerous studies, the pathway of aggregation from soluble
α-helical-rich or partially unfolded peptides into insoluble
β-sheet-rich amyloid fibrils remains unclear. Several studies
discovered parameters of peptide environment, like pH [12,13],
oxidative stress [14], presence of organic components [15,16] or
metal ions [17,18], to have a crucial influence on the conforma-
tional transition. The challenging physicochemical properties,
the low solubility and the tendency to aggregate make natural
amyloid-forming peptides difficult to synthesize and compli-
cates detailed structural characterization. One possibility to
overcome these problems is the use of de novo designed model
peptides [19]. The identification of short domains in peptide se-
quence which make a peptide prone to amyloid formation [20-
23] inspired the design of a series of amyloid-forming model
peptides with defined characteristics, outstanding stability,
regular fibrous architecture and high synthetic accessibility with
numerous chemoselective ligation and modification methods
[24-26]. Also, various post-translational modifications, like
phosphorylation or glycosylation have been studied as aggrega-
tion triggers [27-29]. Phosphorylation caused by abnormal ac-
tivities of phosphatases and/or kinases is associated with known
diseases such as cancer [30], multiple sclerosis [31], diabetes
[32] and Alzheimer’s disease [33]. The accumulation of hyper-
phosphorylated tau protein as trigger for several dementias was
intensively discussed [33-35]. Moreover, the effect of enzy-
matic phosphorylation on Alzheimer-relevant APP was demon-
strated already decades ago [36] and has been followed up in
plenty of studies since then [37-40]. Phosphorylation experi-
ments were also transferred to model peptide systems by our
group. We explored a 26-residue coiled-coil peptide which
undergoes a conformational transition to amyloid fibrils in
24 hours under physiological conditions [41], but remains
random coil if one of three serine residues carries a phosphate
group [27]. The aggregation process could be restored by addi-
tion of Lambda Protein Phosphatase that removes the phos-
Scheme 1: Helical wheel projection of two parallel helical strands and
primary structure of KFM6. The recognition motif KFM6(20–24) for
PKA is given in bold and valine residues are bold and underlined.
phate group [42]. It is widely accepted that this reversible
process of phosphorylation directs diverse properties of
peptides or proteins in nature, ranging from interactions with
other proteins and nucleic acids to subcellular localization and
binding [43]. Additionally, phosphorylation may be found to
direct desired behaviors in the currently intensively studied area
of amyloid-based biomaterials. In this report we show the use of
the negatively charged phosphate group to control the aggrega-
tion process. Using PKA and ATP (adenosine triphosphate) as
phosphate group donor, we studied the impact of the phosphate
group on the oligomerization pathway at different conforma-
tional states from random coil, over β-sheet monomers to
protofilaments and amyloid fibrils. Furthermore, we demon-
strate the importance of the influence of phosphorylation com-
ponents on the peptide conformation during this process. This
knowledge could become a useful tool in employing enzymatic
phosphorylation and dephosphorylation as triggers for or inhibi-
tors of amyloid formation, as it was previously shown for a self-
assembling, supramolecular hydrogel [44].
Results
Peptide model
Peptide KFM6 follows a typical coiled-coil heptad repeat se-
quence and it includes five amino acids (-R-R-A-S-L-) in posi-
tions 20–24, in proximity to the C-terminus, that serve as the
recognition motif for PKA. The crucial role of this recognition
motif for efficient phosphorylation has long been established
[45]. It is also known that enzyme activity depends upon the
local flexibility and solvent-exposed position of the target
amino acid in the peptide [46]. Scheme 1 depicts the key design
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Figure 1: a) Time-dependent CD spectra and b) corresponding CD-minimum plot for random coil (black) and β-sheet (grey) of 15 µM KFM6 in 50 mM
Tris/HCl buffer with 10 mM MgCl2 at pH 7.5 and 24 °C.
features, which are based on one of our previously published
peptides [47], and the primary structure of KFM6. The non-
polar leucine residues at positions a and d contribute to thermal
stability by hydrophobic core packing of the leucine zipper
motif (“knobs-into-holes principle”). Charged amino acids at
positions e, g, b, and c stabilize the coiled-coil by intramolecu-
lar electrostatic attractions between glutamates and lysines.
Intermolecular coulombic interactions between e and g direct
the monomers into a parallel dimeric orientation. The solvent-
exposed position f is occupied by serine for better solubility.
One site of each position b, c, and f contains valine, making the
system prone to amyloid formation. To ensure the UV-activity
of the peptide as analytical tool, Abz (anthranilic acid) was
coupled to the N-terminus. The resulting peptide contains ele-
ments of α-helices and β-sheets, and a recognition site for PKA.
To investigate the structural changes that KFM6 undergoes in
the absence of phosphorylation, time-dependent CD (circular
dichroism) measurements were performed. To ensure compa-
rable and reproducible starting conditions, a disaggregation and
concentration validation assay using HFIP (1,1,1,3,3,3-hexa-
fluoropropan-2-ol) was performed. Thus, all aggregates that
may have formed during peptide synthesis and purification were
disrupted.
As shown in Figure 1 the peptide KFM6 adopts a random struc-
ture upon dissolution in buffer and undergoes a time-resolved
conformational transition to β-sheet-rich amyloid fibrils within
24 hours. The CD spectra (Figure 1a) show a typical minimum
at 200 nm indicating a random-coil conformation with decreas-
ing intensity over 24 hours, and another increasing minimum at
218 nm, which is characteristic for β-sheets [48]. Absolute
values of ellipticity IΘI for 200 or 218 nm are plotted versus the
time (Figure 1b) for better visualization.
Although a white precipitate indicates the formation of aggre-
gates, amyloid fibril formation was studied by means of a ThT
(thioflavine T) binding assay (Figure 2). ThT yields in an en-
hanced fluorescence signal at 485 nm when bound to amyloid
fibrils, and can be used to determine the kinetics of fibril forma-
tion [49]. KFM6 shows a strongly increasing fluorescence
signal without lag time, reaching a plateau after ten hours
(Figure 2, circles).
Figure 2: ThT-binding assay of of 15 µM KFM6 in 50 mM Tris/HCl
buffer with 10 mM MgCl2 at pH 7.5, 24 °C, and a ThT concentration of
20 µM. The amyloid growth process was monitored for untreated
peptide (circles) and peptide in the presence of PKA and ATP (trian-
gles). All values were determined in triplicate and are normalized
based on the initial fluorescence intensity (t = 5 min; λ = 485 nm).
The displayed data indicate a fast amyloid growth process that
appears to begin upon dissolution in buffer. This observation is
in good agreement with the CD spectra, in which no lag time
was observed. To discover the morphology of the amyloid
fibrils, a TEM (transmission electron micrograph) was obtained
at 24 hours of incubation (Figure 3a). The TEM shows typical
amyloid morphologies such as extended tubular fibers, some of
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Figure 3: a) TEM micrograph of 15 µM KFM6 in 50 mM Tris/HCl buffer with 10 mM MgCl2 at pH 7.5 and 24 °C. The peptide was incubated for 24 h in
a closed cuvette in the presence of 5000 U PKA and 200 µM ATP and stained with 1% PTA (phosphortungstic acid). b) Time-dependent CD spectra
of 30 µM PCKFM6 in 50 mM Tris/HCl buffer with 10 mM MgCl2 pH 7.5 and 24 °C.
them ending in funnels. The protofilaments are frequently well
resolved. Their spacing is about 3.5 nm, which is in good agree-
ment with estimates for the protofilaments of other related
peptides [47].
Enzymatic phosphorylation
To investigate the influence of enzymatic phosphorylation on
the aggregation process, buffer containing PKA and ATP was
prepared and used to dissolve lyophilized KFM6. PKA is the
most studied and structurally well-characterized protein kinase,
and it is known to have relatively broad substrate specificity due
to its roles in the regulation of energy metabolism, growth,
signal transduction, and apoptosis of cells [50]. The serine/thre-
onine kinase PKA uses ATP as phosphate donor. It has to be
activated from its natural species with cAMP which leads to
dissociation of PKA in two regular and two catalytic subunits
[51]. We used the preactivated catalytic subunit of PKA to
perform the reactions. The structural behavior of KFM6 during
enzymatic phosphorylation was determined by different analyti-
cal methods.
The ThT binding assay shows no increase in amyloid formation
compared to the unphosphorylated sample over 24 hours
(Figure 2, triangles) and the CD-minimum plot indicates a large
population of random structures and a constantly low intensity
for β-sheets over seven days of incubation (Figure 4a). Together
with the TEM micrograph, which shows no sign of amyloid
morphologies or other higher oligomers, the results suggest the
inhibition of amyloid formation of KMF6 by enzymatic phos-
phorylation. Also, no precipitation was observed during all
enzymatic phosphorylation experiments, which is a further indi-
cator for less aggregate formation.
To learn more about the influence of phosphorylation compo-
nents on the pathway of aggregation and at which state the
growth of oligomers is stopped by phosphorylation, we per-
formed time-dependent enzymatic phosphorylation studies.
Therefore, ATP and PKA were added separately at time zero
and the other one was added after a certain time assuming that
the phosphorylation of KFM6 begins immediately when both
phosphorylation components are present in solution. In this
way, the influence of ATP or PKA on amyloid fibril formation
was monitored as control. In Figure 4b, the persistent minimum
at 218 nm for β-sheets and the apparent absence of a random-
coil structure suggest that ATP accelerates the aggregation
process, which is in a good agreement with previous studies in
which organic anions were found to enhance the formation of
amyloid fibrils [16]. When, after a five minute incubation time
of KFM6 with ATP, PKA is added, the concentration of
β-sheets decreases and the minimum at 200 nm for random
structures strongly increases (Figure 4b). This conformational
transition shows a strong directing effect of enzymatic phos-
phorylation in the early stages of aggregate growth, during
which small oligomers and protofilaments prevail. If the peptide
was incubated with PKA for two hours (Figure 4d), the soluble
peptide concentration decreases, what could be an effect of
aggregation. After two hours and induced phosphorylation, the
peptide concentration and structure seems to be stabilized over
at least seven days. The inverse experiment, with ATP incuba-
tion for two hours, results in an intensive increase of β-sheet
structures in KFM6 (Figure 4c). After induced phosphorylation,
the concentration of β-sheets decreased in good agreement with
the previous observation. To further clarify the conformational
shift the 200/218 nm ratio of some CD experiments was
depicted in Supporting Information File 1 (Figure S3).
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Figure 4: a) Enzymatic phosphorylation of 15 µM KFM6 in time-dependent CD-minimum plots. Addition of both 200 µM ATP and 5000 U PKA at time
of dissolution of peptide; b) ATP-induced β-sheet formation, reversed by the addition of PKA after five minutes of incubation; c) the influence of ATP
during the first two hours of conformational change and effect of two hours delayed phosphorylation; and d) the inverse experiment with PKA.
Chemical phosphorylation
To demonstrate the directing effect of the phosphate group
towards soluble random structures, chemically phosphorylated
PCKFM6 was synthesized for control experiments. The peptide
was dissolved in HFIP stock solution, as was unphosphorylated
KFM6. For CD experiments PCKFM6 was prepared in two-fold
higher concentration (30 µM) compared to KFM6, with the
intention to make it more prone to aggregation. However, only
random structures were observed after seven days (Figure 3b).
A TEM was taken 24 hours after dissolving and incubating the
peptide. PCKFM6 shows no morphologies of amyloid fibrils, its
preliminary states or other higher order oligomers. Also no
precipitation was observed. These results indicate high stability
of the chemically phosphorylated peptide in comparison to the
unphosphorylated analog.
Discussion
In the accepted model pathway of amyloid formation, a lag
phase populated by functional soluble peptide structures is fol-
lowed by partial unfolding, then a conformational transition into
β-sheet monomers follows and these assemble into oligomers
and protofilaments which then form amyloid fibrils [26,52].
While most inhibition studies concentrate on the later phase of
this process, the results we present here suggest a strong
directing effect to random structures during the initial phase of
the aggregation process concomitant with enzymatic phosphor-
ylation. Phosphorylation experiments at different time points of
the aggregation process suggest a time-dependent inhibitory
effect, which becomes less efficient with increasing concentra-
tion of amyloid fibrils. The impact of phosphorylation must be
considered with respect to three properties: steric bulk, charge
and hydrophobicity. It was calculated that phosphorylation in-
creases the van der Waals volume of the serine side chain by a
factor of two [27] and it seems natural that flexible structures
and solvent exposed positions should be preferred for both the
interaction of the recognition site with the enzyme and the re-
sulting, bulky phosphate group. Nevertheless, comparative
studies between phosphate and β-galactose, incorporated in an
amyloid forming coiled-coil peptide, showed no significant
structural influence of the three times larger sugar residue,
whereas the phosphate group directed the peptide into unfolded
structures [27]. Additionally, the phosphate group introduces a
formal charge of −2 to the peptide at pH 7.5. This leads to intra-
molecular Coulombic repulsions between negatively charged
glutamate residues and the phosphate, or in electrostatic pairing
with positively charged lysine or arginine residues, resulting in
the perturbation of higher ordered secondary structures [53].
The impact of electrostatics on peptide and protein folding and
self-assembly has been studied extensively [12,53], and it is
known that the impact of the phosphate group charge strongly
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depends on the pH and the neighboring residues in the peptide
[53,54]. In contrast to the accepted model where negatively
charged phosphates must be close to the N-terminus to have a
stabilizing effect on the original secondary structure [55], we
demonstrate that phosphorylation proximal to the C-terminus
can also significantly inhibit amyloid formation.
Delayed ATP or PKA addition lead in all cases to a stop of the
amyloid formation and to stabilization of remaining soluble
structures, as no further precipitation was observed. It remains
unclear whether the decreasing effect of the phosphorylation
during later stages of the aggregation is due to the lower flexi-
bility of the recognition site, leading to slow reaction kinetics of
the enzyme or to the competitive effects of nucleation-induced
aggregation and phosphorylation. 31P NMR experiments
displaying the enzymatic phosphorylation over 12 hours with
measurements every 30 minutes suggest rapid phosphorylation,
as no change in the integral ratio of β-phosphate to α-phosphate
of ATP was observed subsequent to the first time point (Sup-
porting Information File 1, Figure S4). These observations
support the theory that fully formed aggregates in a protofila-
mental or amyloidal stage cannot be accessed by the enzyme.
This could be either a consequence of the low solubility or the
tight cross-β-structure of the amyloid fibrils [56]. Furthermore,
the presence of amyloid fibrils is known to have a strong
promoting effect on the aggregation process [57,58], whereby
nucleation, together with the unfavorable structure could
conceal the effect of phosphorylation. Thus, a further proof was
the chemically phosphorylated peptide PCKFM6 which com-
pletely lost its ability to undergo a conformational transition and
remains random coil even at higher concentrations.
The conformational transition to the β-sheet-rich structures is
provided by the incorporation of hydrophobic domains, which
can also decrease the overall solubility of the peptide. Calcu-
lated secondary structure propensities, using the TANGO algo-
rithm, identify a nine amino acid long β-aggregation domain
(E-L-V-V-L-K-S-E-L-) for KFM6 (Supporting Information
File 1, Figure S5). Those aggregation domains are found in
almost every peptide with the propensity to form amyloids
[59,60]. The recognition site for PKA is located next to the
aggregation domain of KFM6, with just three amino acids dis-
tance to the phosphorylated serine residue. The short distance to
this hydrophobic aggregation domain could enable an interac-
tion with the polar phosphate group, resulting in the suppres-
sion of the β-aggregation propensity. This is in accordance with
simulations carried out by Rousseau et al. who proposed that
charged amino acid residues flanking aggregating peptide seg-
ments could act as gatekeeper residues that reduce the aggrega-
tion propensity of the peptide [61-63]. Nevertheless, the change
of the serine in position 23 of KFM6 to a glutamic acid does not
influence the calculated propensities to form β-aggregates as the
phosphorylation does (Supporting Information File 1, Figure
S5). It has also been reported that not only the charge, but also
the position of the phosphate group can influence the amyloid
formation and even the morphology of the formed fibrils
[54,64]. Determining the relative contributions of the above
factors to the role of phosphorylation in the amyloid forming
pathway is a major challenge, however, crucial for the molecu-
lar understanding of the process.
Conclusion
Post-translational modifications like phosphorylation have
become the most promising approach to examine and control
the pathway of amyloid fibrillization. For a better under-
standing of the challenges of phosphorylation in this context,
we designed a model peptide which undergoes a conformation-
al transition from soluble structures to amyloids under physio-
logical conditions and additionally presents a recognition site
for PKA. During the initial growth phase, in which small
oligomers and protofilaments are assumed to prevail, our results
demonstrate a remarkable directing effect towards unfolded
structures, if the peptide was phosphorylated close to the hydro-
phobic aggregation domain of the peptide. However, the enzy-
matic phosphorylation had to be realised on flexible secondary
structures and couldn’t dissipate grown aggregates in our exper-
iments. The ability to identify those influences is a major chal-
lenge to use enzymatic phosphorylation as a tool to control the
aggregation process and for the development of new functional
biomaterials based on amyloid morphologies.
Experimental
Peptide synthesis, purification and characteri-
zation
Peptides were synthesized manually according to standard
Fmoc chemistry using preloaded Fmoc-Leu-NovaSyn®TGA
resin (0.3 mmol g−1, Novabiochem). Standard couplings were
performed in DMF with Fmoc-amino acids and TBTU
(O-(benzotriazole-1-yl)-N,N,N’,N’-tetramethyluronium tetra-
fluoroborate)/HOBt (1-hydroxybenzotriazole)/DIC (N,N’-diiso-
propylcarbodiimide) in eight-fold and NaClO4 in ten-fold
excess with double couplings of one hour coupling time. Fmoc-
Ser(PO(OBzl)OH)-OH was activated with HATU (O-(7-
azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexa-
fluorophosphate)/HOBt five-fold and fifteen-fold excess of
DIPEA (N,N-diisopropylethylamine) with respect to the resin
and two hour double couplings. A mixture of DBU (1,8-diaza-
bicyclo[5,4,0]undec-7-ene) and piperidine (2% each) in DMF
was used for Fmoc-deprotection (3 × 10 min). The resin was
washed between each step with DMF and DCM (3 × 6 mL
each). Peptides were cleaved from the resin by treatment with
2 mL TFA (trifluoroacetic acid/iPr3SiH/H2O (90:9:1)) for three
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hours. The resin was washed twice with 1 mL TFA and DCM,
and excess of solvent was removed by evaporation. The
peptides were precipitated with cold Et2O, pelleted by centrifu-
gation and dried by lyophilization. All peptides were purified
with preparative reversed-phase HPLC by using a Knauer
Smartline system (Knauer, Berlin, Germany) equipped with a
Luna C8 column (10 u, 250 × 21.20 mm, Phenomenex,
Torrance, CA, USA) running with a ACN/ H2O + 0.1% TFA
gradient at a flow rate of 20 mL min−1 flow. The crude peptide
was dissolved in 5 mL ACN/H2O/DMSO (1:1:1). The collected
fractions were evaporated and the purified peptide was dis-
solved in 2 mL of water and lyophilized to give the peptide as a
white powder. Pure peptides were characterized by means of
analytical HPLC and ESI–ToF mass spectrometry. Analytical
HPLC was carried out with a VWR-Hitachi Elite LaCrome
system (VWR, Darmstadt, Germany) using a Luna C8 column
(5 u, 250 × 4.6 mm, Phenomenex, Torrance, CA, USA). The
mass to charge ratios were determined with an Agilent 6210
ESI–ToF (Agilent Technologies, Santa Clara, CA, USA).
Peptide solutions were injected by a syringe pump with a flow
rate of 20 µL min−1. Spray voltage was set to 4000 V, drying
gas flow rate was 5 L min−1 and gas temperature was set to
300 °C. Both retention times and peptide masses are given in
Supporting Information File 1 (Table S1).
Concentration determination
A stock solution was prepared by dissolving the purified, Abz
labeled peptide in HFIP (≈1 mg mL−1) and sonicating for
15 minutes to dissolve all aggregates. 50 µL of this solution
were aliquoted and dried under nitrogen flow, before the residue
was dissolved in 1 mL 50 mM Tris/HCl buffer containing
10 mM MgCl2 at pH 7.5. UV spectra were recorded in a 1 cm
path length cuvette using a Cary 50 UV–vis spectrophotometer
(Varian, Palo Alto, CA, USA) and the absorbance maximum at
312 nm was compared to a standard curve of the dipeptide
H2N-Abz-Gly-OH·HCl to calculate the concentration of the
peptide stock solution. The stock solution was stored at −20 °C.
Circular dichroism
CD spectra were recorded by using a Jasco J-810 spectropo-
larimeter (Jasco, Gross-Umstadt, Germany) at 24 °C (Jasco
PTC-348W1 peltier thermostat) using 0.2 mm path length
Quartz Suprasil cuvettes (Hellma, Müllheim, Germany). After
background correction, the spectra were averaged over three
scans (λ = 195–240 nm; 0.5 nm intervals; 2 mm bandwidth; 4 s
response time, 100 nm min−1 scanning speed). Ellipticity was
normalized to concentration (c [mol L−1]), number of residues
(n = 27, including the N-terminal Abz group) and path length
(l [cm]) by using Equation 1 in which Θobs is the measured
ellipticity in millidegrees and Θ is the mean residue ellipticity in
103 mdeg cm2 dmol−1 residue−1.
(1)
Aliquots of the peptide stock solution were dried under nitrogen
flow and, immediately before measurement, dissolved in 350
µL 50 mM Tris/HCl buffer with 10 mM MgCl2, including 5000
U PKA and 200 µM ATP for the enzymatic phosphorylation
studies. The pH was adjusted to 7.5 with 1 M NaOH. For time-
dependent phosphorylation experiments, the buffer was pre-
pared with just one of the phosphorylation components, while
the other one was added at different time points.
Thioflavin T fluorescence spectroscopy
Fluorescence spectra were recorded by using a 1 cm path length
quartz cuvette (Hellma, Müllheim, Germany) and a lumines-
cence spectrometer LS50B (Perkin-Elmer, Boston, MA, USA).
Spectra were recorded at room temperature from 470−500 nm
after excitation at 450 nm (excitation slit width 5 nm; emission
slit width 20 nm; scan speed = 500 nm min−1; accumulations =
5). Sample preparation was the same as for CD with a volume
of 500 µL buffer including 20 µM ThT. The fluorescence inten-
sity at 485 nm was recorded at different time points over a total
time period of 24 hours and normalized to the starting value at
t = 5 min of one. The shown plots represent an average of three
independent measurements.
Transmission electron microscopy
Peptides, prepared as for CD spectroscopy measurements, were
examined after 24 hours. Aliquots (6 µL) of the corresponding
solution were placed for 60 seconds onto glow-discharged (60 s
plasma treatment at 8 W in BAL-TEC MED 020), carbon-
coated collodium films on 400-mesh copper grids (Leica
Microsystems, Wetzlar, Germany). After blotting and negative
staining with 1% PTA, the grids were left to air-dry. The TEM
images were recorded with a Philips CM12 transmission elec-
tron microscope (FEI, Oregon, USA) at 100 kV acceleration
voltage and at a primary magnification of 58000× on Kodak
SO-163 negative film by using a defocus of 900 nm.
Supporting Information
Supporting Information File 1




We would like to thank Dr. Allison Berger and Dr. Johann
Moschner for proofreading the manuscript and Dr. Andreas
Schäfer for carrying out the 31P NMR experiments. We would
Beilstein J. Org. Chem. 2016, 12, 2462–2470.
2469
further like to acknowledge the assistance of the Core Facility
BioSupraMol supported by the DFG.
References
1. Chiti, F.; Dobson, C. M. Annu. Rev. Biochem. 2006, 75, 333–366.
doi:10.1146/annurev.biochem.75.101304.123901
2. Cherny, I.; Gazit, E. Angew. Chem., Int. Ed. 2008, 47, 4062–4069.
doi:10.1002/anie.200703133
3. DeToma, A. S.; Salamekh, S.; Ramamoorthy, A.; Lim, M. H.
Chem. Soc. Rev. 2012, 41, 608–621. doi:10.1039/C1CS15112F
4. Seeman, P.; Seeman, N. Synapse 2011, 65, 1289–1297.
doi:10.1002/syn.20957
5. Westermark, P. Upsala J. Med. Sci. 2011, 116, 81–89.
doi:10.3109/03009734.2011.573884
6. Vandenberghe, R. Curr. Neurol. Neurosci. Rep. 2014, 14, No. 498.
doi:10.1007/s11910-014-0498-9
7. Baldwin, A. J.; Bader, R.; Christodoulou, J.; MacPhee, C. E.;
Dobson, C. M.; Barker, P. D. J. Am. Chem. Soc. 2006, 128,
2162–2163. doi:10.1021/ja0565673
8. Perutz, M. F.; Finch, J. T.; Berriman, J.; Lesk, A.
Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 5591–5595.
doi:10.1073/pnas.042681399
9. Yang, F.; Lim, G. P.; Begum, A. N.; Ubeda, O. J.; Simmons, M. R.;
Ambegaokar, S. S.; Chen, P. P.; Kayed, R.; Glabe, C. G.;
Frautschy, S. A.; Cole, G. M. J. Biol. Chem. 2005, 280, 5892–5901.
doi:10.1074/jbc.M404751200
10. Maji, S. K.; Perrin, M. H.; Sawaya, M. R.; Jessberger, S.;
Vadodaria, K.; Rissman, R. A.; Singru, P. S.; Nilsson, K. P. R.;
Simon, R.; Schubert, D.; Eisenberg, D.; Rivier, J.; Sawchenko, P.;
Vale, W.; Riek, R. Science 2009, 325, 328–332.
doi:10.1126/science.1173155
11. Fowler, D. M.; Koulov, A. V.; Alory-Jost, C.; Marks, M. S.; Balch, W. E.;
Kelly, J. W. PLoS Biol. 2006, 4, e6, 100–107.
doi:10.1371/journal.pbio.0040006
12. Pagel, K.; Wagner, S. C.; Araghi, R. R.; von Berlepsch, H.;
Böttcher, C.; Koksch, B. Chem. – Eur. J. 2008, 14, 11442–11451.
doi:10.1002/chem.200801206
13. Aggeli, A.; Bell, M.; Carrick, L. M.; Fishwick, C. W. G.; Harding, R.;
Mawer, P. J.; Radford, S. E.; Strong, A. E.; Boden, N.
J. Am. Chem. Soc. 2003, 125, 9619–9628. doi:10.1021/ja021047i
14. Bieschke, J.; Zhang, Q.; Powers, E. T.; Lerner, R. A.; Kelly, J. W.
Biochemistry 2005, 44, 4977–4983. doi:10.1021/bi0501030
15. Klajnert, B.; Cladera, J.; Bryszewska, M. Biomacromolecules 2006, 7,
2186–2191. doi:10.1021/bm060229s
16. Lendel, C.; Bolognesi, B.; Wahlström, A.; Dobson, C. M.; Gräslund, A.
Biochemistry 2010, 49, 1358–1360. doi:10.1021/bi902005t
17. Cerasoli, E.; Sharpe, B. K.; Woolfson, D. N. J. Am. Chem. Soc. 2005,
127, 15008–15009. doi:10.1021/ja0543604
18. Karr, J. W.; Kaupp, L. J.; Szalai, V. A. J. Am. Chem. Soc. 2004, 126,
13534–13538. doi:10.1021/ja0488028
19. Pagel, K.; Koksch, B. Curr. Opin. Chem. Biol. 2008, 12, 730–739.
doi:10.1016/j.cbpa.2008.09.005
20. Scrocchi, L. A.; Chen, Y.; Waschuk, S.; Wang, F.; Cheung, S.;
Darabie, A. A.; McLaurin, J.; Fraser, P. E. J. Mol. Biol. 2002, 318,
697–706. doi:10.1016/S0022-2836(02)00164-X
21. Tenidis, K.; Waldner, M.; Bernhagen, J.; Fischle, W.; Bergmann, M.;
Weber, M.; Merkle, M.-L.; Voelter, W.; Brunner, H.; Kapurniotu, A.
J. Mol. Biol. 2000, 295, 1055–1071. doi:10.1006/jmbi.1999.3422
22. Balbach, J. J.; Ishii, Y.; Antzutkin, O. N.; Leapman, R. D.; Rizzo, N. W.;
Dyda, F.; Reed, J.; Tycko, R. Biochemistry 2000, 39, 13748–13759.
doi:10.1021/bi0011330
23. Melquiond, A.; Gelly, J.-C.; Mousseau, N.; Derreumaux, P.
J. Chem. Phys. 2007, 126, 065101. doi:10.1063/1.2435358
24. Elgersma, R. C.; van Dijk, M.; Dechesne, A. C.; van Nostrum, C. F.;
Hennink, W. E.; Rijkersa, D. T. S.; Liskamp, R. M. J.
Org. Biomol. Chem. 2009, 7, 4517–4525. doi:10.1039/b912851d
25. Chaudhary, N.; Nagaraj, R. J. Pept. Sci. 2011, 17, 115–123.
doi:10.1002/psc.1339
26. Hackenberger, C. P. R.; Schwarzer, D. Angew. Chem., Int. Ed. 2008,
47, 10030–10074. doi:10.1002/anie.200801313
27. Broncel, M.; Falenski, J. A.; Wagner, S. C.; Hackenberger, C. P. R.;
Koksch, B. Chem. – Eur. J. 2010, 16, 7881–7888.
doi:10.1002/chem.200902452
28. Artner, L. M.; Merkel, L.; Bohlke, N.; Beceren-Braun, F.; Weise, C.;
Dernedde, J.; Budisa, N.; Hackenberger, C. P. R. Chem. Commun.
2012, 48, 522–524. doi:10.1039/C1CC16039G
29. Shumyantseva, V. V.; Suprun, E. V.; Bulko, T. V.; Archakov, A. I.
Biosens. Bioelectron. 2014, 61, 131–139.
doi:10.1016/j.bios.2014.05.001
30. Nakamura, K.; Shima, H.; Watanabe, M.; Haneji, T.; Kikuchi, K.
Biochem. J. 1999, 344, 819–825. doi:10.1042/bj3440819
31. Auch, C. J.; Saha, R. N.; Sheikh, F. G.; Liu, X.; Jacobs, B. L.;
Pahan, K. FEBS Lett. 2004, 563, 223–228.
doi:10.1016/S0014-5793(04)00302-3
32. Hutton, J. C.; Eisenbarth, G. S. Proc. Natl. Acad. Sci. U. S. A. 2003,
100, 8626–8628. doi:10.1073/pnas.1633447100
33. Eidenmüller, J.; Fath, T.; Hellwig, A.; Reed, J.; Sontag, E.; Brandt, R.
Biochemistry 2000, 39, 13166–13175. doi:10.1021/bi001290z
34. Beharry, C.; Cohen, L. S.; Di, J.; Ibrahim, K.; Briffa-Mirabella, S.;
Alonso, A. del C. Neurosci. Bull. 2014, 30, 346–358.
doi:10.1007/s12264-013-1414-z
35. Russell, C. L.; Koncarevic, S.; Ward, M. A. J. Alzheimer's Dis. 2014,
41, 345–364. doi:10.3233/JAD-132312
36. Gandy, S.; Czernik, A. J.; Greengard, P. Proc. Natl. Acad. Sci. U. S. A.
1988, 85, 6218–6221. doi:10.1073/pnas.85.16.6218
37. Hung, A. Y.; Haass, C.; Nitsch, R. M.; Qiu, W. Q.; Citron, M.;
Wurtman, R. J.; Growdon, J. H.; Selkoe, D. J. J. Biol. Chem. 1993, 268,
22959–22962.
38. Chen, Y.-X.; Du, J.-T.; Zhou, L.-X.; Liu, X.-H.; Zhao, Y.-F.;
Nakanishi, H.; Li, Y.-M. Chem. Biol. 2006, 13, 937–944.
doi:10.1016/j.chembiol.2006.06.017
39. Liang, Z.; Liu, F.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C.-X.
J. Neurochem. 2007, 103, 2462–2470.
doi:10.1111/j.1471-4159.2007.04942.x
40. Liu, X.-A.; Zhu, L.-Q.; Zhang, Q.; Shi, H.-R.; Wang, S.-H.; Wang, Q.;
Wang, J.-Z. Neurochem. Res. 2008, 33, 1811–1820.
doi:10.1007/s11064-008-9638-4
41. Gerling, U. I. M.; Brandenburg, E.; von Berlepsch, H.; Pagel, K.;
Koksch, B. Biomacromolecules 2011, 12, 2988–2996.
doi:10.1021/bm200587m
42. Broncel, M.; Wagner, S. C.; Hackenberger, C. P. R.; Koksch, B.
Chem. Commun. 2010, 46, 3080–3082. doi:10.1039/c001460e
43. Hirsch, A. K. H.; Fischer, F. R.; Diederich, F. Angew. Chem., Int. Ed.
2007, 46, 338–352. doi:10.1002/anie.200603420
44. Yang, Z.; Liang, G.; Wang, L.; Xu, B. J. Am. Chem. Soc. 2006, 128,
3038–3043. doi:10.1021/ja057412y
45. Zetterqvist, Ö.; Ragnarsson, U. FEBS Lett. 1982, 139, 287–290.
doi:10.1016/0014-5793(82)80872-7
Beilstein J. Org. Chem. 2016, 12, 2462–2470.
2470
46. Kreegipuu, A.; Blom, N.; Brunak, S.; Järv, J. FEBS Lett. 1998, 430,
45–50. doi:10.1016/S0014-5793(98)00503-1
47. Pagel, K.; Wagner, S. C.; Samedov, K.; von Berlepsch, H.;
Bottcher, C.; Koksch, B. J. Am. Chem. Soc. 2006, 128, 2196–2197.
doi:10.1021/ja057450h
48. Greenfield, N.; Fasman, G. D. Biochemistry 1969, 8, 4108–4116.
doi:10.1021/bi00838a031
49. Levine, H., III. Protein Sci. 1993, 2, 404–410.
doi:10.1002/pro.5560020312
50. Meinkoth, J. L.; Alberts, A. S.; Went, W.; Fantozzi, D.; Taylor, S. S.;
Hagiwara, M.; Montminy, M.; Feramisco, J. R. Mol. Cell. Biochem.
1993, 127, 179–186. doi:10.1007/BF01076769
51. Kim, C.; Cheng, C. Y.; Saldanha, S. A.; Taylor, S. S. Cell 2007, 130,
1032–1043. doi:10.1016/j.cell.2007.07.018
52. Pagel, K.; Vagt, T.; Koksch, B. Org. Biomol. Chem. 2005, 3,
3843–3850. doi:10.1039/b510098d
53. Inoue, M.; Hirata, A.; Tainaka, K.; Morii, T.; Konno, T. Biochemistry
2008, 47, 11847–11857. doi:10.1021/bi8010994
54. Valette, N. M.; Radford, S. E.; Harris, S. A.; Warriner, S. L.
ChemBioChem 2012, 13, 271–281. doi:10.1002/cbic.201100607
55. Inoue, M.; Konno, T.; Tainaka, K.; Nakata, E.; Yoshida, H.; Morii, T.
Biochemistry 2012, 51, 1396–1406. doi:10.1021/bi201451z
56. Hamley, I. W. Angew. Chem., Int. Ed. 2007, 46, 8128–8147.
doi:10.1002/anie.200700861
57. Bernhardt, N. A.; Berhanu, W. M.; Hansmann, U. H. E.
J. Phys. Chem. B 2013, 117, 16076–16085. doi:10.1021/jp409777p
58. O'Nuallain, B.; Williams, A. D.; Westermark, P.; Wetzel, R.
J. Biol. Chem. 2004, 279, 17490–17499. doi:10.1074/jbc.M311300200
59. Fernandez-Escamilla, A.-M.; Rousseau, F.; Schymkowitz, J.;
Serrano, L. Nat. Biotechnol. 2004, 22, 1302–1306.
doi:10.1038/nbt1012
60. Azriel, R.; Gazit, E. J. Biol. Chem. 2001, 276, 34156–34161.
doi:10.1074/jbc.M102883200
61. Rousseau, F.; Schymkowitz, J.; Serrano, L. Curr. Opin. Struct. Biol.
2006, 16, 118–126. doi:10.1016/j.sbi.2006.01.011
62. Rousseau, F.; Serrano, L.; Schymkowitz, J. W. H. J. Mol. Biol. 2006,
355, 1037–1047. doi:10.1016/j.jmb.2005.11.035
63. Pedersen, J. S.; Christensen, G.; Otzen, D. E. J. Mol. Biol. 2004, 341,
575–588. doi:10.1016/j.jmb.2004.06.020
64. Schneider, A.; Biernat, J.; von Bergen, M.; Mandelkow, E.;
Mandelkow, E.-M. Biochemistry 1999, 38, 3549–3558.
doi:10.1021/bi981874p
License and Terms
This is an Open Access article under the terms of the
Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
The license is subject to the Beilstein Journal of Organic
Chemistry terms and conditions:
(http://www.beilstein-journals.org/bjoc)
The definitive version of this article is the electronic one
which can be found at:
doi:10.3762/bjoc.12.240
